Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1612 1613 1614 1617
This examiner grants 39% of resolved cases
Sean M. Basquill is an examiner in Art Unit 1612 within Tech Center 1600. He has a history of 1069 resolved cases. The allowance rate for these cases is 38.8 percent, which points to a restrictive examination environment. Applicants should also note the median time to allowance of 1239 days, which indicates that the prosecution process often requires a significant time investment before a grant is issued.
The data reveals an interview lift of 21.7 percent. This lift is an improvement over the 38.8 percent baseline allowance rate, suggesting that oral advocacy is a valuable strategy when working with Basquill. Given the 1069 resolved cases, this 21.7 percent lift is a well-supported trend that practitioners should leverage to improve their chances of success. The 1239 days median pendency highlights the importance of using every available tool, including interviews, to move applications toward a resolution in Art Unit 1612.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18824391 | SUSTAINED RELEASE BIODEGRADABLE INTRACANALICULAR INSERTS COMPRISING A HYDROGEL AND CYCLOSPORINE | Non-Final OA | Ocular Therapeutix, Inc. |
| 18726302 | INTRACANALICULAR INSERT COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | Non-Final OA | OCULAR THERAPEUTIX, INC. |
| 19533595 | PHARMACEUTICAL COMPOSITION | Non-Final OA | MEXICHEM FLUOR S.A. DE C.V. |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | Non-Final OA | Allergan, Inc. |
| 18535180 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | Non-Final OA | The Johns Hopkins University |
| 18990308 | HAIR CARE COMPOSITIONS WITH MAILLARD REACTION INHIBITING ENZYMES | Non-Final OA | HENKEL AG & CO. KGAA |
| 17936208 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18832440 | IONIZABLE LIPIDS, LIPID NANOPARTICLES, AND USES THEREOF | Non-Final OA | Verily Life Sciences LLC |
| 18044877 | PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18692447 | PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTION OR TREATMENT OF OSTEOARTHRITIS | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18756828 | PET SHAMPOOS, PET FOOD COMPOSITIONS, AND REGIMENS AND/OR METHODS THEREOF | Non-Final OA | Hill's Pet Nutrition, Inc. |
| 18292286 | COMPOSITION FOR LIGHTENING KERATIN FIBRES, COMPRISING A PEROXYGENATED SALT, CARBONATE AND/OR AMMONIUM BICARBONATE AND AT LEAST 1% OF A POLYPHOSPHORUS DERIVATIVE | Non-Final OA | L'Oreal |
| 18685853 | COMPOSITE NANOPARTICULATE MINERALIZED COLLAGEN GLYCOSAMINOGLYCAN MATERIALS WITH TIME RELEASE ANTI-RESORPTIVE FACTORS | Final Rejection | The Board of Trustees of the University of Illinois |
| 17810142 | STABLE CYCLODEXTRIN FREE CARFILZOMIB FORMULATION | Final Rejection | AMGEN INC. |
| 18540254 | CATIONIC AMPHIPHILIC POLYMERS FOR CODELIVERY OF HYDROPHOBIC AGENTS AND NUCLEIC ACIDS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 17788266 | HAIR COSMETIC COMPOSITION | Non-Final OA | KAO CORPORATION |
| 18845312 | AGROCHEMICAL EMULSIFIABLE COMPOSITION | Final Rejection | Nippon Kayaku Kabushiki Kaisha |
| 18552434 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | Final Rejection | Impact Therapeutics (Shanghai), Inc |
| 18171406 | Intravaginal Ring Device for the Delivery of Aromatase Inhibitor | Final Rejection | Celanese EVA Performance Polymers LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy